Beta-adrenergic receptor blockers and liver cancer mortality in a national cohort of hepatocellular carcinoma patients

References

• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–386.
   PubMed Web of Science ®Google Scholar
• Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391(10125):1023–1075.
   PubMed Web of Science ®Google Scholar
• Costanzo ES, Sood AK, Lutgendorf SK. Biobehavioral influences on cancer progression. Immunol Allergy Clin North Am. 2011;31(1):109–132.
   PubMed Web of Science ®Google Scholar
• Cole SW, Sood AK. Molecular pathways: beta-adrenergic signaling in cancer. Clin Cancer Res. 2012;18(5):1201–1206.
   PubMed Web of Science ®Google Scholar
• Choi CH, Song T, Kim TH, et al. Meta-analysis of the effects of beta blocker on survival time in cancer patients. J Cancer Res Clin Oncol. 2014;140(7):1179–1188.
   PubMed Web of Science ®Google Scholar
• Weberpals J, Jansen L, Carr PR, et al. Beta blockers and cancer prognosis – the role of immortal time bias: a systematic review and meta-analysis. Cancer Treat Rev. 2016;47:1–11.
   PubMed Web of Science ®Google Scholar
• Melhem-Bertrandt A, Chavez-Macgregor M, Lei X, et al. Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. JCO. 2011;29(19):2645–2652.
   PubMed Web of Science ®Google Scholar
• Botteri E, Munzone E, Rotmensz N, et al. Therapeutic effect of beta-blockers in triple-negative breast cancer postmenopausal women. Breast Cancer Res Treat. 2013;140(3):567–575.
   PubMed Web of Science ®Google Scholar
• Kawai Y, Powell A, Arinze IJ. Adrenergic receptors in human liver plasma membranes: predominance of beta 2- and alpha 1-receptor subtypes. J Clin Endocrinol Metab. 1986;62(5):827–832.
   PubMed Web of Science ®Google Scholar
• Kassahun WT, Gunl B, Tannapfel A, et al. Alpha1-and beta2-adrenoceptors in the human liver with mass-forming intrahepatic cholangiocarcinoma: density and coupling to adenylate cyclase and phospholipase C. Naunyn Schmied Arch Pharmacol. 2005;372(3):171–181.
   PubMed Web of Science ®Google Scholar
• Li J, Yang XM, Wang YH, et al. Monoamine oxidase A suppresses hepatocellular carcinoma metastasis by inhibiting the adrenergic system and its transactivation of EGFR signaling. J Hepatol. 2014;60(6):1225–1234.
   PubMed Web of Science ®Google Scholar
• Wu FQ, Fang T, Yu LX, et al. ADRB2 signaling promotes HCC progression and sorafenib resistance by inhibiting autophagic degradation of HIF1alpha. J Hepatol. 2016;65(2):314–324.
   PubMed Web of Science ®Google Scholar
• Bevilacqua M, Norbiato G, Chebat E, et al. Changes in alpha-1 and beta-2 adrenoceptor density in human hepatocellular carcinoma. Cancer. 1991;67(10):2543–2551.
   PubMed Web of Science ®Google Scholar
• Kassahun WT, Guenl B, Ungemach FR, et al. Expression and functional coupling of liver beta2 – adrenoceptors in the human hepatocellular carcinoma. Pharmacology. 2012;89(5–6):313–320.
   PubMed Web of Science ®Google Scholar
• Chen D, Xing W, Hong J, et al. The beta2-adrenergic receptor is a potential prognostic biomarker for human hepatocellular carcinoma after curative resection. Ann Surg Oncol. 2012;19(11):3556–3565.
   PubMed Web of Science ®Google Scholar
• Wang F, Liu H, Wang F, et al. Propranolol suppresses the proliferation and induces the apoptosis of liver cancer cells. Mol Med Rep. 2018;17(4):5213–5221.
   PubMed Web of Science ®Google Scholar
• İşeri ÖD, Sahin FI, Terzi YK, et al. beta-Adrenoreceptor antagonists reduce cancer cell proliferation, invasion, and migration. Pharm Biol. 2014;52(11):1374–1381.
   PubMed Web of Science ®Google Scholar
• Thiele M, Albillos A, Abazi R, et al. Non-selective beta-blockers may reduce risk of hepatocellular carcinoma: a meta-analysis of randomized trials. Liver Int. 2015;35(8):2009–2016.
   PubMed Web of Science ®Google Scholar
• Yu D, Holmes S, Uhanova J, et al. Predicting hepatocellular carcinoma recurrence and survival. Hepatogastroenterology. 2014;61(131):776–783.
   PubMedGoogle Scholar
• Chang PY, Chung CH, Chang WC, et al. The effect of propranolol on the prognosis of hepatocellular carcinoma: a nationwide population-based study. PLOS One. 2019;14(5):e0216828.
   PubMed Web of Science ®Google Scholar
• Barlow L, Westergren K, Holmberg L, et al. The completeness of the Swedish Cancer Register: a sample survey for year 1998. Acta Oncol. 2009;48(1):27–33.
   PubMed Web of Science ®Google Scholar
• Wettermark B, Hammar N, MichaelFored C, et al. The new Swedish Prescribed Drug Register – opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidem Drug Safe. 2007;16(7):726–735.
   PubMed Web of Science ®Google Scholar
• Weberpals J, Jansen L, van Herk-Sukel MPP, et al. Immortal time bias in pharmacoepidemiological studies on cancer patient survival: empirical illustration for beta-blocker use in four cancers with different prognosis. Eur J Epidemiol. 2017;32(11):1019–1031.
   PubMed Web of Science ®Google Scholar
• Udumyan R, Montgomery S, Fang F, et al. Beta-blocker drug use and survival among patients with pancreatic adenocarcinoma. Cancer Res. 2017;77(13):3700–3707.
   PubMed Web of Science ®Google Scholar
• Ludvigsson JF, Andersson E, Ekbom A, et al. External review and validation of the Swedish national inpatient register. BMC Public Health. 2011;11(1):450.
   PubMed Web of Science ®Google Scholar
• Sjöberg H. Statistics Sweden. Swedish registers – a gold mine for medical research; 2016. http://epc2014.princeton.edu/papers/140708.
   Google Scholar
• Johansson LA, Westerling R. Comparing Swedish hospital discharge records with death certificates: implications for mortality statistics. Int J Epidemiol. 2000;29(3):495–502.
   PubMed Web of Science ®Google Scholar
• Lambert PC, Royston P. Further development of flexible parametric models for survival analysis. The Stata Journal. 2009;9(2):265–290.
   Web of Science ®Google Scholar
• Royston P, Sauerbrei W. Building multivariable regression models with continuous covariates in clinical epidemiology–with an emphasis on fractional polynomials. Methods Inf Med. 2005;44(04):561–571.
   PubMed Web of Science ®Google Scholar
• Montomoli J, Erichsen R, Norgaard M, et al. Survival of patients with primary liver cancer in central and northern Denmark. Clin Epidemiol. 2011. 1998;3(2009):3–10.
   Google Scholar
• Mandorfer M, Reiberger T. Beta blockers and cirrhosis, 2016. Dig Liver Dis. 2017;49(1):3–10.
   PubMedGoogle Scholar
• Desai A, Sandhu S, Lai JP, et al. Hepatocellular carcinoma in non-cirrhotic liver: a comprehensive review. WJH. 2019;11(1):1–18.
   PubMed Web of Science ®Google Scholar
• Garcia-Tsao G, Sanyal AJ, Grace ND, Practice Guidelines Committee of the American Association for the Study of Liver Diseases, the Practice Parameters Committee of the American College of Gastroenterology, et al. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology. 2007;46(3):922–938.
   PubMed Web of Science ®Google Scholar
• Giannelli V, Lattanzi B, Thalheimer U, et al. Beta-blockers in liver cirrhosis. Ann Gastroenterol. 2014;27(1):20–26.
   PubMedGoogle Scholar
• Senzolo M, Cholongitas E, Burra P, et al. beta-Blockers protect against spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis. Liver Int. 2009;29(8):1189–1193.
   PubMed Web of Science ®Google Scholar
• Hernandez-Gea V, Aracil C, Colomo A, et al. Development of ascites in compensated cirrhosis with severe portal hypertension treated with beta-blockers. Am J Gastroenterol. 2012;107(3):418–427.
   PubMed Web of Science ®Google Scholar
• Schutte K, Schulz C, Poranzke J, et al. Characterization and prognosis of patients with hepatocellular carcinoma (HCC) in the non-cirrhotic liver. BMC Gastroenterol. 2014;14(1):117.
   PubMed Web of Science ®Google Scholar
• Zhang ZF, Feng XS, Chen H, et al. Prognostic significance of synergistic hexokinase-2 and beta2-adrenergic receptor expression in human hepatocelluar carcinoma after curative resection. BMC Gastroenterol. 2016;16(1):57.
   PubMed Web of Science ®Google Scholar
• Cole SW, Nagaraja AS, Lutgendorf SK, et al. Sympathetic nervous system regulation of the tumour microenvironment. Nat Rev Cancer. 2015;15(9):563–572.
   PubMed Web of Science ®Google Scholar
• Perez-Sayans M, Somoza-Martin JM, Barros-Angueira F, et al. Beta-adrenergic receptors in cancer: therapeutic implications. Oncol Res. 2010;19(1):45–54.
   PubMed Web of Science ®Google Scholar
• Baker JG. The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors. Br J Pharmacol. 2005;144(3):317–322.
   PubMed Web of Science ®Google Scholar
• Vandenbroucke J, Pearce N. Point: incident exposures, prevalent exposures, and causal inference: does limiting studies to persons who are followed from first exposure onward damage epidemiology? Am J Epidemiol. 2015;182(10):826–833.
   PubMed Web of Science ®Google Scholar
• Fitzgerald PJ. Beta blockers, norepinephrine, and cancer: an epidemiological viewpoint. Clin Epidemiol. 2012;4:151–156.
   PubMedGoogle Scholar
• Danaei G, Tavakkoli M, Hernan MA. Bias in observational studies of prevalent users: lessons for comparative effectiveness research from a meta-analysis of statins. Am J Epidemiol. 2012;175(4):250–262.
   PubMed Web of Science ®Google Scholar
• Grobbee DE, Hoes AW. Confounding and indication for treatment in evaluation of drug treatment for hypertension. BMJ. 1997;315(7116):1151–1154.
   PubMed Web of Science ®Google Scholar
• Pinter M, Trauner M, Peck-Radosavljevic M, et al. Cancer and liver cirrhosis: implications on prognosis and management. ESMO Open. 2016;1(2):e000042.
   PubMed Web of Science ®Google Scholar
• Moctezuma-Velazquez C, Kalainy S, Abraldes JG. Beta-blockers in patients with advanced liver disease: Has the dust settled? Liver Transpl. 2017;23(8):1058–1069.
   PubMed Web of Science ®Google Scholar